HeartSciences Posts FQ1 2027 Loss; Fortitude Merger Remains on Track for Q4 Close
HSCS has more than doubled off its 52-week low of $1.63.
Summary
HeartSciences reported a $3.2 million FQ1 2027 net loss and a $2.0 million shareholders' deficit, but disclosed $2.4 million in recent financing (Fortitude subscription, ATM sales, note conversion) with no merger exchange ratio adjustment, plus first US commercial agreements for MyoVista Insights.
Key Events · Earnings and Guidance · HSCS
-
FQ1 2027 Net Loss of $3.2M
Loss from operations was $2.9 million, up from $1.9 million a year ago, driven by $0.5 million in merger-related legal costs, $0.5 million in non-cash share-based compensation, and a $0.3 million inventory reserve.
-
$2.4M Raised Without Exchange Ratio Adjustment
Fortitude subscribed for $1.0 million of common stock in August 2026, the company raised $1.2 million net from ATM sales, and $200,000 of note principal converted to equity — none of which adjusted the merger exchange ratio, avoiding additional dilution for existing holders.
-
MyoVista Insights Commercial Traction
First US commercial agreements signed following full launch, and selection as the ECG management and AI-ECG delivery platform for a clinical program at a major European reference center.
-
wavECG Device Written Down
Company recorded a $0.3 million inventory reserve against the MyoVista wavECG device and does not intend to commit significant additional resources to its commercialization, citing reduced commercial rationale for a proprietary device.
Analysis · HSCS · Crypto Assets
HeartSciences disclosed its fiscal Q1 2027 results alongside a business update that materially advances the picture for shareholders. The company posted a $3.2 million net loss with a $2.0 million shareholders' deficit, but the more consequential news is the financing activity: Fortitude subscribed for $1.0 million of HeartSciences stock in August 2026, the company raised $1.2 million net from its ATM facility, and $200,000 of promissory note principal was converted to equity — all without adjusting the merger exchange ratio. This means existing shareholders avoid additional dilution from these capital raises. The MyoVista Insights platform also hit its first US commercial agreements and won a European reference center selection, while the legacy wavECG device was effectively written down with a $0.3 million inventory reserve. Against the backdrop of a going-concern warning and near-zero cash, these financing lifelines and commercial traction are meaningful, though the company remains dependent on the Fortitude merger closing in Q4 2026.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HSCS was trading at $3.44 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $13.4M. The 52-week trading range was $1.63 to $4.35. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.